Gain Therapeutics Stock Market Value
| GANX Stock | USD 1.74 0.01 0.58% |
| Symbol | Gain |
Gain Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gain Therapeutics. If investors know Gain will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gain Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.07) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (1.89) |
The market value of Gain Therapeutics is measured differently than its book value, which is the value of Gain that is recorded on the company's balance sheet. Investors also form their own opinion of Gain Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gain Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gain Therapeutics' market value can be influenced by many factors that don't directly affect Gain Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gain Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gain Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gain Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Gain Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Gain Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Gain Therapeutics.
| 10/30/2024 |
| 11/29/2024 |
If you would invest 0.00 in Gain Therapeutics on October 30, 2024 and sell it all today you would earn a total of 0.00 from holding Gain Therapeutics or generate 0.0% return on investment in Gain Therapeutics over 30 days. Gain Therapeutics is related to or competes with In8bio, Cue Biopharma, Tff Pharmaceuticals, Lantern Pharma, Eliem Therapeutics, Inhibrx, and Enliven Therapeutics. Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by pr... More
Gain Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Gain Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Gain Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.3 | |||
| Information Ratio | 0.0775 | |||
| Maximum Drawdown | 36.84 | |||
| Value At Risk | (10.78) | |||
| Potential Upside | 14.68 |
Gain Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Gain Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Gain Therapeutics' standard deviation. In reality, there are many statistical measures that can use Gain Therapeutics historical prices to predict the future Gain Therapeutics' volatility.| Risk Adjusted Performance | 0.0811 | |||
| Jensen Alpha | 0.5758 | |||
| Total Risk Alpha | (0.44) | |||
| Sortino Ratio | 0.0799 | |||
| Treynor Ratio | 0.6549 |
Gain Therapeutics Backtested Returns
Gain Therapeutics is very risky given 3 months investment horizon. Gain Therapeutics holds Efficiency (Sharpe) Ratio of 0.15, which attests that the entity had a 0.15% return per unit of risk over the last 3 months. We were able to interpolate twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.07% are justified by taking the suggested risk. Use Gain Therapeutics Market Risk Adjusted Performance of 0.6649, downside deviation of 7.3, and Risk Adjusted Performance of 0.0811 to evaluate company specific risk that cannot be diversified away. Gain Therapeutics holds a performance score of 11 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 1.07, which attests to a somewhat significant risk relative to the market. Gain Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Gain Therapeutics is expected to follow. Use Gain Therapeutics sortino ratio, as well as the relationship between the semi variance and rate of daily change , to analyze future returns on Gain Therapeutics.
Auto-correlation | 0.25 |
Poor predictability
Gain Therapeutics has poor predictability. Overlapping area represents the amount of predictability between Gain Therapeutics time series from 30th of October 2024 to 14th of November 2024 and 14th of November 2024 to 29th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Gain Therapeutics price movement. The serial correlation of 0.25 indicates that over 25.0% of current Gain Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.25 | |
| Spearman Rank Test | -0.01 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Gain Therapeutics lagged returns against current returns
Autocorrelation, which is Gain Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Gain Therapeutics' stock expected returns. We can calculate the autocorrelation of Gain Therapeutics returns to help us make a trade decision. For example, suppose you find that Gain Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Gain Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Gain Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Gain Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Gain Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Gain Therapeutics Lagged Returns
When evaluating Gain Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Gain Therapeutics stock have on its future price. Gain Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Gain Therapeutics autocorrelation shows the relationship between Gain Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Gain Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.